Sociedad Americana de Hirudoterapia

Comparative transcriptomic analyses of three species of Placobdella confirms a single origin of blood feeding in leeches

Comparative transcriptomics published in Journal of Parasitology (2015)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyGenómica y proteómicaFarmacología salivalSiddall ME et al. · The Journal of parasitology, 2015

Abstract

One of the recalcitrant questions regarding the evolutionary history of clitellate annelids involves the feeding preference of the common ancestor of extant rhynchobdellid (proboscis bearing) and arhynchobdellid (jaw bearing) leeches. Whereas early evidence, based on morphological data, pointed towards independent acquisitions of blood feeding in the 2 orders, molecular-based phylogenetic data suggest that the ancestor of modern leeches was a sanguivore. Here, we use a comparative transcriptomic approach in order to increase our understanding of the diversity of anticoagulation factors for 3 species of the genus Placobdella, for which comparative data have been lacking, and inspect these in light of archetypal anticoagulant data for both arhynchobdellid and other rhynchobdellid species. Notwithstanding the varying levels of host specificity displayed by the 3 different species of Placobdella, transcriptomic profiles with respect to anticoagulation factors were largely similar -this despite the fact that Placobdella kwetlumye only retains a single pair of salivary glands, as opposed to the 2 pairs more common in the genus. Results show that 9 different anticoagulant proteins and an additional 5 putative antihemostasis proteins are expressed in salivary secretions of the 3 species. In particular, an ortholog of the archetypal, single-copy, anticoagulant hirudin (not previously available as comparative data for rhynchobdellids) is present in at least 2 of 3 species examined, corroborating the notion of a single origin of blood feeding in the ancestral leech.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsBase SequenceDNA, ComplementaryGene Expression ProfilingGene LibraryHirudinsLeechesOpen Reading FramesProtein Processing, Post-TranslationalProtein Sorting Signals

Resumen

Compares salivary transcriptomes of three Placobdella species; confirms phylogenetically single origin of leech hematophagy and shared antithrombotic gene families.

Por qué esto importa para la hirudoterapia

This study used a comparative transcriptomic approach to examine anticoagulation factors in the salivary secretions of three species of the genus Placobdella, for which comparative data had been lacking. Nine anticoagulant proteins and five additional putative antihemostasis proteins were identified across the three species, and an ortholog of the anticoagulant hirudin was found in at least two of the three species, corroborating the notion of a single origin of blood feeding in the ancestral leech. The work provides descriptive data on anticoagulant-related transcripts in this leech genus. The primary limitation is that the study is focused on evolutionary and comparative biology; the abstract makes no therapeutic claims and does not address hirudotherapy or clinical applications.

Citación

Comparative transcriptomic analyses of three species of Placobdella confirms a single origin of blood feeding in leeches.

Siddall ME et al. · The Journal of parasitology, 2015

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.